SABS Latest Headlines

SAB Biotherapeutics (SABS) Gets a Buy from Oppenheimer

at www.tipranks.com (Thu, 23-Apr 7:55 AM)

Buy Rating on SABS Driven by SAB-142’s Differentiated T1D Mechanism, Durable C-Peptide Preservation, and Pivotal SAFEGUARD Catalyst

at www.tipranks.com (Wed, 22-Apr 12:25 PM)

Wall Street Analysts Are Bullish on Top Healthcare Picks

at www.tipranks.com (Wed, 22-Apr 9:41 AM)

SAB Biotherapeutics Highlights Positive Phase 1 SAB-142 Results

at www.tipranks.com (Wed, 22-Apr 8:30 AM)

SAB BIO Closes $85 Million Public Offering to Propel Development of T1D Therapy

Market Chameleon (Fri, 20-Mar 11:26 AM)

SAB BIO’s SAB-142 Shows Early Promise in Preserving Insulin Production in Type 1 Diabetes Phase 1 Study

Market Chameleon (Wed, 11-Mar 10:34 AM)